VOL: 102, ISSUE: 16, PAGE NO: 32Generic and proprietary names
Generic and proprietary names
- Active against the erythrocytic stage of the plasmodium species.
- Prophylaxis of malaria in areas with a high risk of chloroquine-resistant falciparum malaria.
- History of neuropsychiatric disorders including depression and convulsions.
- Hypersensitivity to quinine.
- Pregnancy - avoid pregnancy while taking and for three months after.
- Severe hepatic impairment.
- Cardiac conduction disorders.
- Infants under three months of age or less than 5kg in weight.
- Nausea, vomiting, diarrhoea and abdominal pain.
- Dizziness and loss of balance.
- Sleep disorders.
- Neuropsychiatric reactions.
- Tinnitus and vestibular disorders.
- Visual disturbances.
- Circulatory and cardiac problems.
- Myalgia and arthralgia.
- Fever and malaise.
- Loss of appetite.
- Leucopenia or leucocytosis.
- Other antimalarial drugs.
- Calcium-channel blockers.
- Digitalis drugs.
- Taken only once a week.
- Start 2.5 weeks before entering endemic area and continue for four weeks after leaving.
- Mefloquine doses in the BNF may differ from those in product literature.
- Travellers should be informed about adverse reactions and, if they occur, that they should seek medical advice on alternative antimalarials before the next dose is due.
- Travel to malarious areas should be avoided during pregnancy; if it is unavoidable, effective prophylaxis must be used but mefloquine should be avoided as a matter of principle. However, studies of mefloquine use in pregnancy (including in the first trimester) indicate that it can be considered for travel to chloroquine-resistant areas.
- Mefloquine is considered to be appropriate for use by people with renal impairment and does not require dosage reduction.
- Warn travellers they should still avoid mosquito bites.
- Ensure travellers understand the importance of taking prophylaxis regularly.
- Advise travellers to seek urgent medical attention if ill within one year and especially within three months of return.
- Dizziness or a disturbed sense of balance may affect performance of skilled tasks such as driving.
- The patient information leaflet that describes adverse reactions should always be provided with mefloquine.
Nurses should refer to manufacturer's summary of product characteristics and to appropriate local guidelines